adeno-associated virus vector AAV- CNGA3
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achromatopsia
Conditions
Achromatopsia
Trial Timeline
Aug 12, 2019 → Jun 10, 2021
NCT ID
NCT03758404About adeno-associated virus vector AAV- CNGA3
adeno-associated virus vector AAV- CNGA3 is a phase 1/2 stage product being developed by MeiraGTx for Achromatopsia. The current trial status is completed. This product is registered under clinical trial identifier NCT03758404. Target conditions include Achromatopsia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03758404 | Phase 1/2 | Completed |
Competing Products
2 competing products in Achromatopsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AAV - CNGB3 | MeiraGTx | Phase 1/2 | 33 |
| Prior exposure to AAV-CNGA3 or AAV-CNGB3 | MeiraGTx | Pre-clinical | 15 |
Other Products from MeiraGTx
AAV RPE65Phase 1/2
33
AAV - CNGB3Phase 1/2
33
AAV2hAQP1Phase 1
25
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)Phase 1
25
AAV OPTIRPE65Pre-clinical
15